A Clinical Evaluation of the Effects of Topically Applied Levobunolol and Timolol on Increased Intraocular Pressure

Duzman, Efraim; Ober, M; Scharrer, Amin; Leopold, Irving H.

doi:10.1016/0002-9394(82)90357-9

Cited by 44 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The criteria for exclusion from the study included (1) known contraindications to the topical or systemic use of /3-blocking agents; (2) aphakia, chronic ocular inflam¬ mation, history of intraocular surgery, or any corneal abnormalities preventing reliable applanation tonometry; (3) severe glaucoma uncontrolled by concomitant administration of two or more antiglauco¬ ma drugs; (4) severe diabetes requiring frequent changes in insulin dosage; (5) contact lens wear during the study; (6) the use of adrenergic-augmenting psychotropic,^-blocking, or steroid medications dur¬ ing the study; (7) complete blood cell or blood chemistry analyses suggesting the presence of disease; and (8) pregnancy, anticipated pregnancy, or nursing. Written informed consent was obtained from all study participants.…”

Section: Methodsmentioning

confidence: 99%

Levobunolol Compared With Timolol for the Long-term Control of Elevated Intraocular Pressure

Berson

Cohen

Foerster³

et al. 1985

Archives of Ophthalmology

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Levobunolol Compared With Timolol for the Long-term Control of Elevated Intraocular Pressure

Berson

Cohen

Foerster³

et al. 1985

Archives of Ophthalmology

View full text Add to dashboard Cite

“…Short-term studies of 0.5% and 1% levobunolol (112) and 0.3% to 2% levobunolol (113) showed dose dependent reductions in pressure in glaucomatous eyes without substantial side effects. In a one month trial, levobunolol (1%) was as effective as timolol (0.5%) in reducing IOP in glaucoma patients but with significant reductions in heart rate and diastolic blood pressure (112). Nadolol (2%) reduced IOP in glaucoma patients equipotent to timolol (0.5%) for four weeks (114).…”

Section: Beta-adrenergic Drugsmentioning

confidence: 97%

A Synopsis of Recent Developments in Antiglaucoma Drugs

McLaughlin¹,

Chiou²

1985

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Open-angle glaucoma is treated primarily with drugs, some of which have been used clinically for years. These drugs include: 1) cholinergic agonists that increase aqueous humor outflow, 2) adrenergic agonists and antagonist that affect both aqueous humor formation and outflow, and 3) carbonic anhydrase inhibitors that decrease aqueous humor formation.Several new classes of drugs are being tested for efficacy and mechanism of action. They include: 1) the D-isomer of timolol that reduces aqueous humor formation without producing adrenergic blockade, 2) dopaminergic agonists and antagonists, including bromocriptine and butyrophenones that reduce intraocular pressure, and 3) cannabinoids that reduce aqueous humor formation and increase outflow.In addition, several other types of drugs, such as prostaglandins, diuretics, Na+,K+-ATPase inhibitors, and adenyl cyclase stimulators are just now beginning to be studied.

show abstract

“…Levobunolol senkt den erhöhten Augeninncndruck bei Patienten mit okulärer Hyper tension und Glaukom [1,2], Levobunolol (0,5 und 1%) erwies sich dabei als ebenso wirksam wie 0,5°/oiges Timolol [3][4][5][6]. Die subjektive Verträglichkeit von Lcvobunolol war ausgezeichnet [4], Metipranolol ist ebenfalls wirksam bei der Behandlung des erhöhten Augeninnendrukkes.…”

Section: Introductionunclassified

Lokale subjektive Verträglichkeit von Levobunolol und Metipranolol in einer Doppelblind-Vergleichsstudie bei Patienten mit erhöhtem intraokularem Druck

et al. 1986

Self Cite

View full text Add to dashboard Cite

We evaluated the ocular comfort of 0.5% levobunolol hydrochloride and 0.6% metipranolol hydrochloride ophthalmic solutions in a randomized, double-masked, paired-comparison clinical trial. The drugs were given twice daily for 7 days to 16 patients with open-angle glaucoma or ocular hypertension. Patients rated comfort in terms of the severity of burning and/or stinging. For both drugs, the severity rating of ocular discomfort was low, averaging between 1 and 2 on a scale of 0–10. At initial and follow-up visits, the mean severity rating of burning or stinging with metipranolol was 2, slightly greater than the mean score of 1 with levobunolol. At 55% (26 of 47) of the patient visits, the patients rated levobunolol as more comfortable than metipranolol. Metipranolol (Betamann; Mann) was rated as more comfortable than levobunolol at only 9% (4 of 47) of the patient visits. The duration of burning and stinging was also rated as longer lasting with metipranolol treatment than with levobunolol (Vistagan; Pharma-Allergan) treatment. Although little ocular discomfort was reported for either drug, the majority of the patients tested rated levobunolol the more comfortable of the two drugs.

show abstract

A Clinical Evaluation of the Effects of Topically Applied Levobunolol and Timolol on Increased Intraocular Pressure

Cited by 44 publications

References 8 publications

Levobunolol Compared With Timolol for the Long-term Control of Elevated Intraocular Pressure

Levobunolol Compared With Timolol for the Long-term Control of Elevated Intraocular Pressure

A Synopsis of Recent Developments in Antiglaucoma Drugs

Lokale subjektive Verträglichkeit von Levobunolol und Metipranolol in einer Doppelblind-Vergleichsstudie bei Patienten mit erhöhtem intraokularem Druck

Contact Info

Product

Resources

About